Kathryn E Stephenson

List of Publications by Citations

Source: https://exaly.com/author-pdf/4042953/kathryn-e-stephenson-publications-by-citations.pdf
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41 papers	2,692 citations	22 h-index	41 g-index
41 ext. papers	3,741 ext. citations	20.2 avg, IF	5.25 L-index

#	Paper	IF	Citations
41	Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *New England Journal of Medicine*, **2021**, 384, 1824-1835	59.2	575
40	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. *Science*, **2016**, 353, 1129-32	33.3	386
39	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. *Nature*, **2016**, 540, 284-287	50.4	183
38	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). *Lancet, The*, **2018**, 392, 232-243	40	170
37	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1535-1544	27.4	139
36	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. *Lancet, The*, **2018**, 391, 563-571	40	126
35	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. *Nature*, **2021**, 596, 268-272	50.4	122
34	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. *Cell*, **2020**, 183, 1354-1366.e13	66.2	108
33	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV,the*, **2019**, 6, e259-e268	7.8	87
32	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. *New England Journal of Medicine*, **2021**, 385, 951-953	59.2	77
31	Zika virus vaccines. *Nature Reviews Microbiology*, **2018**, 16, 594-600	22.2	67
30	Broadly Neutralizing Antibodies for HIV Eradication. *Current HIV/AIDS Reports*, **2016**, 13, 31-7	5.9	62
29	New concepts in HIV-1 vaccine development. *Current Opinion in Immunology*, **2016**, 41, 39-46	7.8	58
28	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. *Cell Host and Microbe*, **2019**, 25, 59-72.e8	23.4	56
27	A global approach to HIV-1 vaccine development. *Immunological Reviews*, **2013**, 254, 295-304	11.3	50
26	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. *Clinical Infectious Diseases*, **2021**, 73, e3996-e4004	11.6	43
25	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. *Annual Review of Immunology*, **2020**, 38, 673-703	34.7	40

24	Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. *Journal of Virology*, **2012**, 86, 11434-40	6.6	40
23	Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. *Journal of Virology*, **2012**, 86, 9583-9	6.6	35
22	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. *Journal of Immunological Methods*, **2015**, 416, 105-23	2.5	31
21	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. *Nature Medicine*, **2020**, 26, 228-235	50.5	30
20	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. *Journal of Infectious Diseases*, **2018**, 218, 633-644	7	23
19	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. *PLoS ONE*, **2018**, 13, e0205139	3.7	20
18	Therapeutic vaccination for HIV: hopes and challenges. *Current Opinion in HIV and AIDS*, **2018**, 13, 408-415	4.2	19
17	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. *Lancet Infectious Diseases, The*, **2020**, 20, 1061-1070	25.5	15
16	Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. *Journal of Infectious Diseases*, **2012**, 205, 1806-10	7	15
15	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. *Annals of Internal Medicine*, **2021**, 174, 585-594	8	14
14	Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4 T cell responses that impair CD8 T cell function. *Science Immunology*, **2016**, 1,	28	12
13	Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. *Open Forum Infectious Diseases*, **2016**, 3, ofw100	1	12
12	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). *Lancet HIV,the*, **2020**, 7, e410-e421	7.8	11
11	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. *Cell Reports*, **2020**, 33, 108502	10.6	10
10	Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 **2021**,		10
9	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. *Journal of Virology*, **2018**, 92,	6.6	8
8	Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. *Vaccine Journal*, **2015**, 22, 1166-75		8
7	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. *Journal of Virology*, **2018**, 92,	6.6	6

6	Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. *Blood Advances*, **2018**, 2, 2917-2921	7.8	6
5	Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. *Journal of Virology*, **2014**, 88, 13510-5	6.6	5
4	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant		5
3	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. *Nature Medicine*, **2021**, 27, 1718-1724	50.5	5
2	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective.. *Open Forum Infectious Diseases*, **2022**, 9, ofac124	1	3
1	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.. *Npj Vaccines*, **2022**, 7, 2	9.5	0